Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma (NCT00715611)
Phase II Toxicity Study of Pleurectomy/Decortication, (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
🩺 Plain-English Summary (8th-Grade Level)
For patients with this type of cancer, the standard of care is treatment with chemotherapy. Radiation therapy is typically not used. This is because radiation to the entire lining of the lung has many side effects that are often severe including damage to the lung (pneumonitis). There is a new radiation technique using Intensity Modulated Radiation Therapy (IMRT) that has been shown to reduce many of the side effects of standard radiation therapy. This type of radiation therapy specifically targets the lining of the lung, where you have your cancer, and reduces the risk of damaging the lung itself. The purpose of this study is to test the safety and implementation of standard pleurectomy/decortication (removal of the surface lining of the lung) and standard chemotherapy followed by IMRT performed at other centers. Patients will undergo pleurectomy/decortication chemotherapy and hemithoracic pleural IMRT to the pleura in patients with malignant pleural mesothelioma.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (15 items) and avoid the listed exclusions (16 items).
Location: Moffitt Cancer Center — Tampa, Florida
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- \> 10% Sarcomatoid or desmoplastic histology
- Continuous oxygen use
- Prior nephrectomy on the contralateral side of MPM
- Prior intrapleural therapy (except pleurodesis) or intrapleural therapy at the time of P/D (i.e.: intrapleural chemotherapy, photodynamic therapy, intrapleural betadine)
- Prior thoracic radiation therapy preventing hemithoracic pleural IMRT
- Bulky disease in the fissure preventing lung-sparing pleural IMRT
- Patients undergoing extrapleural pneumonectomy
- Patients with an active infection that require systemic antibiotics, antiviral, or antifungal treatments
- Patients with a concurrent active malignancy (except squamous or basal cell carcinoma of the skin)
- Patients with serious unstable medical illness
- Presence of third space fluid that cannot be controlled by drainage
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (12 Sites)
- Moffitt Cancer Center — Tampa, Florida
- Brigham and Women's Hospital — Boston, Massachusetts
- Mayo Clinic Cancer Center — Rochester, Minnesota
- Memorial Sloan Kettering at Basking Ridge — Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack — Commack, New York
- Memoral Sloan Kettering Westchester — Harrison, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering at Rockville Center, NY — Rockville Centre, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
- Md Anderson Cancer Center — Houston, Texas
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Mesothelioma
- Olaparib in Patients With HRD Malignant Mesothelioma — Chicago, Illinois
- A Study of Sacituzumab Govitecan in People With Mesothelioma — Basking Ridge, New Jersey
- Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma — Durham, North Carolina
- MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI — Boston, Massachusetts
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma — Baltimore, Maryland
- Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion — Phoenix, Arizona
Explore by condition: All Mesothelioma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.